Cardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az

Similar documents
Learning Objectives. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Is Atherosclerosis a Pediatric Disease?

Page 1. Disclosures. Background. No disclosures

Statistical Fact Sheet Populations

Established Risk Factors for Coronary Heart Disease (CHD)

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2

Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants

Metabolic Syndrome.

How would you manage Ms. Gold

DIAGNOSIS AND TREATMENT OF FH CHILDREN. O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax

Cardiometabolic Side Effects of Risperidone in Children with Autism

Young high risk patients the role of statins Dr. Mohamed Jeilan

Pharmacy Management Drug Policy

Disclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Adolescent Hypertension Roles of obesity and hyperuricemia. Daniel Landau, MD Pediatrics, Soroka University Medical Center

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

Disclosure. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Case Disclosure

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Trial Evidences. Marjet Braamskamp Departement of Vascular Medicine/ Pediatrics Lipidology in Pediatrics 24 September 2015

Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016

Metabolic Syndrome Across the Life Cycle - Adolescent. Joy Friedman MD

Test5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight

Review current guideline recommendations for lipid-lowering therapy

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Repatha. Repatha (evolocumab) Description

3/25/2010. Age-adjusted incidence rates for coronary heart disease according to body mass index and waist circumference tertiles

Risk Factors for Heart Disease

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

How to Reduce Residual Risk in Primary Prevention

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine

Pediatric Dyslipidemia: Angela Gooden MSN, RN, CPNP- AC/PC, Texas Children s Hospital, Pediatric Cardiology

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

Fasting or non fasting?

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

Clinical Study Assessment of Metformin as an Additional Treatment to Therapeutic Lifestyle Changes in Pediatric Patients with Metabolic Syndrome

Repatha. Repatha (evolocumab) Description

Metabolic Syndrome: Why Should We Look For It?

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

MOLINA HEALTHCARE OF CALIFORNIA

EVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378

Health Score SM Member Guide

Identification and management of familial hypercholesterolaemia (FH) - An overview

Cardiovascular disease and diabetes Vascular harmony

Know Your Numbers. The Life Saving Numbers You Need To Know

Cardiovascular Complications of Diabetes

Familial hypercholesterolaemia

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

Contemporary management of Dyslipidemia

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

Metabolic Syndrome in Asians

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

WORKSHOP 1. Management of Patients with Familial Hypercholesterolemia

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)

Elements for a Public Summary

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Selected Overweight- and Obesity- Related Health Disorders

Cardiovascular Disease Risk Factors:

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

LIPID CLUB Rome, 2014

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Prevention of Heart Disease: The New Guidelines

Diabetes Mellitus: A Cardiovascular Disease

4/14/2018 DYSLIPIDEMIA CASES. Mary Malloy, MD. I have nothing to disclose

The American Diabetes Association estimates

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia

Chapter 18. Diet and Health

Know Your Numbers. Your guide to maintaining good health. Helpful information from Providence Medical Center and Saint John Hospital

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Environmental. Vascular / Tissue. Metabolics

High Blood Cholesterol What you need to know

Familial hypercholesterolaemia in children and adolescents

Best Lipid Treatments

Rick Fox M.A Health and Wellness Specialist

Ezetimib Stada 10 mg tablets

Your health is a crucial aspect of your life. That s why the Yakima Heart Center offers this booklet; to help you identify the numbers that affect

STATIN UTILIZATION MANAGEMENT CRITERIA

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

CARDIOVASCULAR HEALTH

Imaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006

Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD

Conceptual Approach to CAD Risk. Disclosures. Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management 2/10/2014.

Atherosclerotic cardiovascular disease (CVD) is the number

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Patient: Shawn Baker March 06, 2018

Inspired Functional Ingredients to Innovate and Differentiate Your Brand. Products by Ecovatec Solutions Inc.

Part 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives.

Transcription:

Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az

No disclosures for this Presentation

Death Risk Approximately 40% of the US population die as the result of Cardiovascular Disease

Question #1 DOES ATHEROSCLEROSIS START IN CHILDREN?

Korean War Autopsy Series 300 autopsies - 73% had some coronary atherosclerosis Mean age = 22.6 yrs 6% had severe lesions 50% or greater narrowing Enos WF, JAMA: 152:1090-93. 1953

Viet War : Autopsy /Coronary Lesions/ US Soldiers 105 autopsies for coronary lesions Mean age = 22.1 yrs 45% had some coronary atherosclerosis 5% had severe Lesions McNamara JJ, JAMA 1971;216(7):1185-1187.

Bogalusa Heart Study 93 deaths with full risk factor data % of patients with with fibrous Coronary Artery plaques by age Berensen G et al NEJM 338:1650-7 1998

Question #2 IS ATHEROSCLEROSIS MORE COMMON IN CHILDREN WITH CVD RISK FACTORS?

Bogalusa: % of total Intima covered by plaque vs # of risk factors But atherosclerosis is never uniform through a vessel

QUESTION # 3 SINCE ATHEROSCLEROSIS STARTS IN CHILDREN, SHOULD WE SCREEN FOR RISK FACTORS IN CHILDREN?

NHLBI Pediatric Screening Recommendations Selective screening of Lipid Profile >2 years of age Universal Screening of Lipid Profile : 9-11 years of age 17-20 years of age every 5 years thereafter Endorsed by: American Academy of Pediatrics American Heart Association National Lipid Association Pediatrics 2011; (Suppl 5) S1-S44

Hetrozygous Familial Hyperlipidemia (FH) was the Original Focus For Screening FH is a loss of function of the gene for the LDL receptor Criteria: Simon-Broome and Dutch Lipid Clinic Suspect FH In children when LDL C > 156 mg/dl 156 high sens, low spec, 190- low sens, high spec Incidence is 1:200-250 in general population Special Populations- incidence is 1:67 Genetic test available with 50% + detection

Is FH Worth Screening For? 1. Mortality for Myocardial Infarct in FH is : 100 X greater than non-fh at ages 20-39 years 4X greater at ages 40-59 years 2. Those with untreated FH have a dramatic increase in coronary vascular disease after 20 years of age 3. Early treatment appears to avoid coronary vascular disease Rx is with statins, ezetimibe, resins, PCSK9 antibodies

Identification of FH Patients by country

Cascade Screening (save a parent, grandparent or other family member) FH is a dominant with very high penetrance Once a patient with FH is identified it is imperative to screen up and down the family tree of the index patient and index case and siblings.

Screening Also Will Detect other Lipid Abnormalities: A. Cholestertol Hyperabsorbers B. Dysfunctional LDL Receptor C. Metabolic Syndrome D. Genetic Triglyceride Disorders E. Low HDL F. Rare Genetic Disorders G. Adverse Reactions to Meds (e.g. acne treatment)

Control of Blood Lipids Normal Value Genetic Control Diet Control Exercise control LDL <100 mg/dl Trigs <90 mg/dl HDL >40 M >50F ++++ +? ++ +++ +++ + +++ ++

NHLBI Lipid Recommendations But where did it come from? Pediatrics 2011; 128:S6 TO AGE 19 Acceptable Borderline High LDL <110 110-129 >130 HDL >45 Trigs <90 90-99 =/>100 20-24 YEARS LDL <120 120-159 >160 HDL >45 Trigs <115 115-149 >150

TIP: FAMILY HISTORY IS VERY IMPORTANT

Other Genetic Dyslipidemias for Kids 1. 10% of population have elevated Lipoprotein (a) 2. 12.5% have cholesterol hyperabsorption (gut) 3. 1-2% have diabetes type 1,2 4. 3% have other genetic dyslipidemias: HeFH, hofh, ARH, gain of function PCSK9, LAL-D Lipoprotein lipase polymorphisms, many others 5. 20% have Metabolic Syndrome due to intraabdominal fat distribution which is determined by genetics.

A New Genetic Factor Association of Maternal Prepregnancy Dyslipidemia With Adult Offspring Dyslipidemia in Excess of Anthropometric, Lifestyle, and Genetic Factors in the Framingham Heart Study Michael M. Mendelson, MD, ScM; Asya Lyass, PhD; Christopher J. O Donnell, MD, MPH; Ralph B. D Agostino Sr, PhD; Daniel Levy, MD CONCLUSIONS AND RELEVANCE Adult offspring dyslipidemia is associated with maternal prepregnancy dyslipidemia in excess of measured lifestyle, anthropometric, and inherited genetic factors. The findings support the possibility of a maternal epigenetic contribution to cardiovascular disease risk in the general population. Further research is warranted to determine whether ongoing public health efforts to identify and reduce dyslipidemia in young adults prior to their childbearing years may have additional potential health benefits for the subsequent generation. JAMA Cardiol. doi:10.1001/jamacardio.2015.0304 Published online March 2, 2016.

Maternal pre-pregnancy LDL

Metabolic Syndrome Criteria for Adults Waist women > 34.5, Men >40 inches Blood Pressure =/> 135 systolic or >85 diastolic HDL <40mg/dl male or <50 mg/dl female Triglycerides =/>100 mg/dl Fasting glucose >100

Relationship between Waist Circumference and Visceral Adipose Tissue Accumulation Subcutaneous adipose tissue Visceral adipose tissue Front Visceral Adipose Tissue (cm 2 ) r = 0.80 60 80 100 120 Waist Circumference (cm) Pouliot MC, et al. Am J Cardiol. 1994;73:460-468; Després JP, et al. BMJ. 2001;322:716-720.

Powerful Central Obesity Detector

Waist/Height Ratio =<.5 = very low probability of MS.5-.6 = Moderate probability of MS =>.6 = very high probability of MS Example 1: waist -31 and height -62 =.5 Example 2:waist -37.2 and height -62 =.6 Khoury et al. J Am Col Cardiol 2013. 62:742-751

Waist/Height Ratio 140 Triglycerides >.6 Fasting Glucose mg/dl 120 100 80 60 40 <.5 mg/dl 95 94 93 92 91 <.5.5-.6 >.6 20 90 0 Waist -Height Ratio 89 Waist/Height Ratio mg/dl 56 54 52 50 48 46 44 42 <5 HDL.5-.6 >.6 IU/ml 25 20 15 10 5 Serum Insulin.5-.6 <5 >.6 40 0 waist/height ratio waist/height Ratio

Carotid IMT

Vijasarthi A, Goldberg SJ Journal of Lipids Volume 2014, Article ID 546863, 7 pages

Metabolic Syndrome- 14 y.o. boy Combination Visceral obesity Increased SQ fat Gynecomastia Note belt position

Change with time Visit 1 Visit 2 Visit 3 Visit 1.5 yrs BMI 34.1 32 31.2 27.2 TSC 232 188 174 176 LDL --- 101 110 114 HDL 28 30 38 42 Trigs 448 283 136 102 Waist (jnch) 44.5 41 38 37 W/H Ratio.66.60.55.53 ALT 224 196 44 28 Glucose 108 104 100 96

How many overweight kids are there??

A Sudden Heart Attack Never Occurs It Takes Years of Preparation

10 yo boy showing LDL change with decreasing Triglycerides 400 350 300 250 200 150 LDL Triglycerides 100 50 0

% LDL Response to Ezetimibe 1/8 of the population does not have haplotype 1735C-25342A-27677T for NPC1L1 gene Hegel RA et al. Lipids in Health and Disease: 2005,4:16

18 year old girl 1. Elevated LDL 142 2. Family history of increased LDL, T2D, MI 3. Mom demanding statin therapy 4. Mild central overweight 5. Uses celexa for anxiety 6. Excessive carbohydrate intake

High LDL + increased waist size 1 st Visit Zetia + Diet BMI 27.2 25.8 TSC 225 164 LDL 142 93 HDL 55 57 Tri 138 71 Wt 149# 141# Ht 62 in 62 in Waist 37 35.4 W/h.59.57

> 2000 persons, ages 15-34 years Atherosclerosis begins in childhood with the appearance of aortic fatty streaks as early as 2 years. Coronary fatty steaks begin to form in adolescence Most persons have coronary fatty streaks by the age 20-29 years. Am J Cardiol. 1998 Nov 26;82(10B):30T-36T.

At 0-18 years, normal fasting triglycerides are: 1. =/<250 2. =/< 150 3. =/ < 90 4. =/< 125 5. =/< 70

Criteria for Metabolic Syndrome include all the following except: 1. BP 2. Waist circumference 3. Triglyceride level 4. HDL Level 5. BMI 6. Serum Glucose

Heterozygous familial hyperlipidemia has a worldwide population frequency of: 1. 1/1,000,000 2. 1/100,000 3. 1/1000 4. 1/200-250 5. 1/67

In the Netherlands 87% of patients with Hetrozygous Familial Hyperlipidemia (HeFH) have been identified. What is the estimated % of HeFH identification in the USA? 1. 60% 2. 95% 3. 25% 4. 10% 5. <2%

The good news is you passed Security, the bad news is you have too much intra-abdominal fat